SOURCE: MedaSorb Technologies Corporation

December 19, 2007 11:27 ET

MedaSorb Initiates Enrollment in Sepsis Clinical Study in Europe

MONMOUTH JUNCTION, NJ--(Marketwire - December 19, 2007) - MedaSorb Technologies Corporation (OTCBB: MSBT) (FRANKFURT: HQE), a medical device company focused on the development of its platform technology for removal of toxins from blood and physiologic fluids, announced that it has opened enrollment in its European Sepsis study. The study is designed to show the effectiveness of MedaSorb's proprietary hemoadsorption device as an adjunctive treatment for acute respiratory distress syndrome and acute lung injury in the setting of sepsis.

The company believes MedaSorb's adsorbent technology may be an effective adjunctive therapy for sepsis by reducing toxic levels of cytokines that have built up in the bloodstream as a result of the body's excessive immune response to infection. President and CEO Al Kraus stated, "We are excited to start our largest clinical study to date, which, if successful, could represent a major breakthrough in the fight against sepsis."

MedaSorb has initiated its first clinical site and will be enrolling up to a total of nine sites for the European study. MedaSorb estimates the study will take between six to nine months to complete. The hospital sites are affiliated with the Vivantes Netzwerk für Gesundheit GmbH; Europe's largest municipal hospital group, comprising nine hospitals and clinics in Berlin, which serve roughly 30 percent of all hospital patients in the German capital. Altogether, Vivantes operates 12 healthcare institutions, with over 5,100 hospital beds and capacity for the full inpatient care of around 1,700 persons.

MedaSorb's clinical study in Germany is intended to support the CE Mark approval process, which will allow MedaSorb to market the CytoSorb™ device throughout the European Union. The company believes this novel therapeutic approach may have a positive impact on the removal of excessive cytokines, which are thought to be key factors in lung dysfunction. The company also believes that by removing these inflammatory cytokines, the CytoSorb™ device may reduce the number of days a patient spends on the ventilator and in turn help reduce mortality.

About Sepsis

Sepsis is a condition that can result from the body's over-response to infection or injury. Sepsis has a mortality rate of up to 60% and affects approx 2 million patients per year in the U.S. and Europe alone. The cost to treat these patients is in excess of $36 Billion. It is the second most frequent cause of death in hospitals outside the cardiac ICU. Severe sepsis is often more dangerous than the initial infection and, without rapid diagnosis and intervention, can develop within a matter of hours, leading to septic shock which can cause temporary or permanent damage to multiple organs or even death.

About MedaSorb

MedaSorb Technologies Corporation is a medical device company preparing to commercialize blood purification technology that effectively removes toxic compounds from blood and physiologic fluids. MedaSorb's initial products, CytoSorb™ and BetaSorb™, are known medically as hemoperfusion devices and incorporate proprietary adsorbent polymer technology. Management believes the potential healthcare applications for its products include: adjunctive treatment of sepsis, prevention of damage to organs donated for transplant prior to organ harvest, prevention of post-operative complications of cardiac surgery, and the short- and long-term treatment of kidney failure. MedaSorb is headquartered in Monmouth Junction, New Jersey.

Safe Harbor Statement

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release are not promises or guarantees and are subject to risks and uncertainties that could cause our actual results to differ materially from those anticipated. These statements are based on management's current expectations and assumptions and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward-looking statements. Actual results may differ materially from those expressed or implied by the statements herein. MedaSorb Technologies Corporation believes that its primary risk factors include, but are not limited to: ability to successfully develop commercial operations; dependence on key personnel; acceptance of the Company's medical devices in the marketplace; the outcome of pending and potential litigation; obtaining government approvals, including required FDA approvals; compliance with governmental regulations; reliance on research and testing facilities of various universities and institutions; the ability to obtain adequate financing in the future when needed; product liability risks; limited manufacturing experience; limited marketing, sales and distribution experience; market acceptance of the Company's products; competition; unexpected changes in technologies and technological advances; and other factors detailed in the Company's latest quarterly report filed with the SEC on November 15, 2007, and other filings which are available at

Contact Information